Why Dyne Therapeutics (DYN) Stock Is Down Today

Dyne Therapeutics (DYN) is down 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is a newly priced upsized common stock offering, which can pressure shares because it increases the share count and is typically priced at a discount to the prior market price. The decline also suggests investors are weighing near-term dilution more heavily than the company’s recent regulatory progress in Duchenne muscular dystrophy.

Details:

Dyne priced an upsized public offering of 18.3 million common shares at $20.50 per share, with gross proceeds expected to be about $375.15 million before fees and expenses.

The company said the proceeds are intended to support development of z-rostudirsen and z-basivarsen, manufacturing scale-up, commercial buildout, additional research programs, and general corporate purposes.

Just two days earlier, Dyne disclosed that the FDA accepted the biologics license application for z-rostudirsen in exon 51 Duchenne muscular dystrophy, granted Priority Review, and set a target action date of January 21, 2027.

That positive regulatory update may have limited the selloff, but offerings often create immediate dilution concerns and can trigger short-term profit-taking after a recent run-up.

Sources:

Dyne Therapeutics, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DYN Insider Trading Activity

$DYN insiders have traded $DYN stock on the open market 108 times in the past 6 months. Of those trades, 7 have been purchases and 101 have been sales.

Here’s a breakdown of recent trading of $DYN stock by insiders over the last 6 months:

JASON P RHODES has made 0 purchases and 73 sales selling 3,102,817 shares for an estimated $63,910,903.
DIRK KERSTEN has made 0 purchases and 17 sales selling 1,614,590 shares for an estimated $31,901,694.
BRIAN S POSNER has made 7 purchases buying 16,000 shares for an estimated $274,840 and 0 sales.
JOHN COX (CEO & President) has made 0 purchases and 3 sales selling 8,726 shares for an estimated $150,676.
ERICK LUCERA (Chief Financial Officer) has made 0 purchases and 2 sales selling 7,175 shares for an estimated $133,336.
DOUGLAS KERR (Chief Medical Officer) has made 0 purchases and 3 sales selling 3,355 shares for an estimated $58,443.
JOHANNA FRIEDL-NADERER (Chief Commercial Officer) has made 0 purchases and 3 sales selling 521 shares for an estimated $9,049.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive DYN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$DYN Hedge Fund Activity

We have seen 122 institutional investors add shares of $DYN stock to their portfolio, and 89 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VESTAL POINT CAPITAL, LP added 3,880,000 shares (+3233.3%) to their portfolio in Q1 2026, for an estimated $70,344,400
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,554,000 shares (-71.9%) from their portfolio in Q1 2026, for an estimated $46,304,020
FMR LLC added 2,339,059 shares (+35.6%) to their portfolio in Q1 2026, for an estimated $42,407,139
ORBIS ALLAN GRAY LTD added 1,960,303 shares (+40.8%) to their portfolio in Q1 2026, for an estimated $35,540,293
FIERA CAPITAL CORP added 1,380,620 shares (+inf%) to their portfolio in Q1 2026, for an estimated $25,030,640
SIREN, L.L.C. removed 1,273,816 shares (-36.4%) from their portfolio in Q1 2026, for an estimated $23,094,284
CANDRIAM S.C.A. removed 1,057,263 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $19,168,178

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DYN Analyst Ratings

Wall Street analysts have issued reports on $DYN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

TD Cowen issued a "Buy" rating on 06/26/2026

To track analyst ratings and price targets for $DYN, check out Quiver Quantitative's $DYN forecast page.

$DYN Price Targets

Multiple analysts have issued price targets for $DYN recently. We have seen 5 analysts offer price targets for $DYN in the last 6 months, with a median target of $38.0.

Here are some recent targets:

Gavin Clark-Gartner from Evercore ISI Group set a target price of $33.0 on 05/15/2026
William Pickering from Bernstein set a target price of $24.0 on 05/13/2026
Keay Nakae from Chardan Capital set a target price of $38.0 on 03/09/2026
Ananda Ghosh from HC Wainwright & Co. set a target price of $50.0 on 03/03/2026
Michael Ulz from Morgan Stanley set a target price of $47.0 on 03/03/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.